AG Edwards Lowers Curagen Rating

An analyst at the firm thinks the stock will trade in line with overall sentiment toward the genomics/biotech sector

AG Edwards downgraded its investment recommendation on shares of Curagen (CRGN ) to hold from strong buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.